BRPI0407726A - compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto - Google Patents
compostos, processo de preparação de um composto, composição farmacêutica e utilização de um compostoInfo
- Publication number
- BRPI0407726A BRPI0407726A BRPI0407726-1A BRPI0407726A BRPI0407726A BR PI0407726 A BRPI0407726 A BR PI0407726A BR PI0407726 A BRPI0407726 A BR PI0407726A BR PI0407726 A BRPI0407726 A BR PI0407726A
- Authority
- BR
- Brazil
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- alkoxy
- nhc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 238000013329 compounding Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 16
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 150000002367 halogens Chemical class 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 abstract 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000005977 Ethylene Substances 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 239000000824 cytostatic agent Substances 0.000 abstract 1
- 230000001085 cytostatic effect Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 230000002584 immunomodulator Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000336 melanocortin receptor agonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 229940125725 tranquilizer Drugs 0.000 abstract 1
- 239000003204 tranquilizing agent Substances 0.000 abstract 1
- 230000002936 tranquilizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
"COMPOSTOS, PROCESSO DE PREPARAçãO DE UM COMPOSTO, COMPOSIçãO FARMACêUTICA E UTILIZAçãO DE UM COMPOSTO". A invenção refere-se a derivados inéditos de benzimidazol e imidazopiridina que apresentam uma boa afinidade com determinados subtipos de receptores de melanocortina, particularmente receptores MC4. Referidos derivados são particularmente interessantes para o tratamento de estados e doenças patológicas envolvendo um ou vários receptores de melanocortina. A invenção refere-se também a composições farmacêuticas contendo referidos produtos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0302320A FR2851563B1 (fr) | 2003-02-26 | 2003-02-26 | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| PCT/FR2004/000418 WO2004075823A2 (fr) | 2003-02-26 | 2004-02-25 | Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0407726A true BRPI0407726A (pt) | 2006-02-14 |
Family
ID=32799584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0407726-1A BRPI0407726A (pt) | 2003-02-26 | 2004-02-25 | compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7355052B2 (pt) |
| EP (1) | EP1599167B1 (pt) |
| JP (1) | JP4714673B2 (pt) |
| KR (1) | KR101074579B1 (pt) |
| CN (1) | CN1753670A (pt) |
| AT (1) | ATE374754T1 (pt) |
| AU (1) | AU2004216427B2 (pt) |
| BR (1) | BRPI0407726A (pt) |
| CA (1) | CA2516660C (pt) |
| DE (1) | DE602004009294T2 (pt) |
| DK (1) | DK1599167T3 (pt) |
| ES (1) | ES2295826T3 (pt) |
| FR (1) | FR2851563B1 (pt) |
| MX (1) | MXPA05009015A (pt) |
| NZ (1) | NZ541632A (pt) |
| PL (1) | PL214244B1 (pt) |
| PT (1) | PT1599167E (pt) |
| RU (1) | RU2330023C2 (pt) |
| WO (1) | WO2004075823A2 (pt) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
| DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
| EP1677791A4 (en) * | 2003-10-31 | 2007-08-15 | Takeda Pharmaceutical | NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS |
| FR2862971B1 (fr) * | 2003-11-28 | 2006-03-24 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament |
| EP1802623A1 (en) * | 2004-10-12 | 2007-07-04 | Novo Nordisk A/S | 11beta-hydroxysteroid dehydrogenase type 1 active spiro compounds |
| US7429608B2 (en) | 2005-01-20 | 2008-09-30 | Amgen Inc. | Benzo[d]imidazol analogs as vanilloid receptor ligands and their use in treatments |
| GB0526042D0 (en) * | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| WO2007091950A1 (en) * | 2006-02-07 | 2007-08-16 | Astrazeneca Ab | Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain |
| WO2007133983A2 (en) * | 2006-05-08 | 2007-11-22 | Pharmacopeia, Inc. | 2-aminobenzimidazoles for treating neurodegenerative diseases |
| EP2072050A1 (en) | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Compounds with anti-emetic effect |
| EP2072516A1 (en) * | 2007-12-21 | 2009-06-24 | Santhera Pharmaceuticals (Schweiz) AG | Substituted imidazopyridine derivates as Melancortin-4 receptor antagonists |
| UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
| EP2348857B1 (en) | 2008-10-22 | 2016-02-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8329914B2 (en) | 2008-10-31 | 2012-12-11 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| WO2010051245A1 (en) * | 2008-11-03 | 2010-05-06 | Merck Sharp & Dohme Corp. | Benzimidazole and aza-benzimidazole carboxamides |
| JP2012518037A (ja) * | 2009-02-18 | 2012-08-09 | アムジエン・インコーポレーテツド | ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物 |
| UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| AU2010263113B2 (en) * | 2009-06-23 | 2015-11-26 | Translational Drug Development, Llc | Benzamide derivatives |
| FR2955105B1 (fr) | 2010-01-11 | 2012-04-20 | Arkema France | Procede de preparation d'aminoethyl imidazolidone ou de son thiocarbonyle |
| US8759535B2 (en) | 2010-02-18 | 2014-06-24 | High Point Pharmaceuticals, Llc | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof |
| DK2536285T3 (en) | 2010-02-18 | 2018-07-16 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives, pharmaceutical compositions and methods for their use |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US20130165426A1 (en) * | 2010-07-06 | 2013-06-27 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
| SG10201505997TA (en) | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
| US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
| US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
| UY33779A (es) | 2010-12-10 | 2012-07-31 | Boehringer Ingelheim Int | ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas? |
| US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
| WO2012100342A1 (en) | 2011-01-27 | 2012-08-02 | Université de Montréal | Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators |
| SG192941A1 (en) | 2011-02-25 | 2013-09-30 | Merck Sharp & Dohme | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| WO2013012848A1 (en) | 2011-07-18 | 2013-01-24 | Merck Patent Gmbh | Benzamides |
| EP2736330A4 (en) * | 2011-07-29 | 2015-05-27 | Tempero Pharmaceuticals Inc | COMPOUNDS AND METHODS |
| AU2012322095B2 (en) | 2011-10-14 | 2017-06-29 | Ambit Biosciences Corporation | Heterocyclic compounds and use thereof as modulators of type III receptor tyrosine kinases |
| LT3539551T (lt) | 2011-12-29 | 2022-01-10 | Rhythm Pharmaceuticals, Inc. | Su melanokortino-4 receptoriumi susijusių sutrikimų gydymo būdas heterozigotiniuose nešiotojuose |
| RU2015106909A (ru) | 2012-08-02 | 2016-09-27 | Мерк Шарп И Доум Корп. | Антидиабетические трициклические соединения |
| KR20150118158A (ko) | 2013-02-22 | 2015-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병 비시클릭 화합물 |
| RU2528110C1 (ru) * | 2013-03-02 | 2014-09-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ увеличения скорости психомоторных реакций анксиолитиком афобазол |
| WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| EP2970388B1 (en) | 2013-03-15 | 2018-07-25 | Rhythm Pharmaceuticals, Inc. | Peptide compositions |
| CN115957297A (zh) | 2013-03-15 | 2023-04-14 | 节奏制药公司 | 药物组合物 |
| CN104072395B (zh) * | 2013-03-25 | 2016-08-24 | 黄蓬 | 一种异硫氰酸酯及其制备方法与抗癌应用 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN105017211A (zh) * | 2014-04-30 | 2015-11-04 | 重庆华邦制药有限公司 | 一种2-苯基丙酸酯衍生物及其制备方法和用途 |
| WO2016089648A1 (en) | 2014-12-01 | 2016-06-09 | Vtv Therapeutics Llc | Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof |
| CN106397288B (zh) * | 2015-07-31 | 2019-04-16 | 深圳超多维科技有限公司 | 联苯类液晶材料的制备方法 |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| EP3558298B1 (en) | 2016-12-20 | 2026-03-11 | Merck Sharp & Dohme LLC | Antidiabetic spirochroman compounds |
| CN111471056B (zh) * | 2019-01-23 | 2021-07-02 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| KR102266854B1 (ko) * | 2019-11-06 | 2021-06-18 | 계명대학교 산학협력단 | 마약 중독 예방 또는 치료용 약학조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3634066A1 (de) * | 1986-10-07 | 1988-04-21 | Boehringer Mannheim Gmbh | Neue 5-alkylbenzimidazole, verfahren zu ihrer herstellung sowie arzneimittel |
| RU2043344C1 (ru) * | 1991-05-20 | 1995-09-10 | Курский Государственный Медицинский Институт | N-2-(1- r1-5-r2-6-r3- бензимидазолил)сукцинаминовые кислоты, проявляющие нейролептическую, антигипоксическую и антиаритмическую активность |
| EP0980359B1 (en) * | 1997-05-01 | 2004-06-23 | Nissan Chemical Industries, Ltd. | Benzimidazole derivative |
| EP1214330A1 (en) * | 1999-09-21 | 2002-06-19 | LION Bioscience AG | Benzimidazole derivatives and combinatorial libraries thereof |
| JP2005509003A (ja) * | 2001-11-09 | 2005-04-07 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物 |
| FR2833948B1 (fr) * | 2001-12-21 | 2004-02-06 | Sod Conseils Rech Applic | Nouveaux derives de benzimidazole et leur utilisation en tant que medicament |
-
2003
- 2003-02-26 FR FR0302320A patent/FR2851563B1/fr not_active Expired - Fee Related
-
2004
- 2004-02-25 US US10/504,033 patent/US7355052B2/en not_active Expired - Fee Related
- 2004-02-25 NZ NZ541632A patent/NZ541632A/en not_active IP Right Cessation
- 2004-02-25 EP EP04714348A patent/EP1599167B1/fr not_active Expired - Lifetime
- 2004-02-25 BR BRPI0407726-1A patent/BRPI0407726A/pt not_active IP Right Cessation
- 2004-02-25 PL PL378288A patent/PL214244B1/pl unknown
- 2004-02-25 MX MXPA05009015A patent/MXPA05009015A/es active IP Right Grant
- 2004-02-25 JP JP2006502162A patent/JP4714673B2/ja not_active Expired - Fee Related
- 2004-02-25 DE DE602004009294T patent/DE602004009294T2/de not_active Expired - Lifetime
- 2004-02-25 WO PCT/FR2004/000418 patent/WO2004075823A2/fr not_active Ceased
- 2004-02-25 CN CNA2004800054133A patent/CN1753670A/zh active Pending
- 2004-02-25 PT PT04714348T patent/PT1599167E/pt unknown
- 2004-02-25 ES ES04714348T patent/ES2295826T3/es not_active Expired - Lifetime
- 2004-02-25 AU AU2004216427A patent/AU2004216427B2/en not_active Ceased
- 2004-02-25 CA CA2516660A patent/CA2516660C/fr not_active Expired - Fee Related
- 2004-02-25 AT AT04714348T patent/ATE374754T1/de active
- 2004-02-25 DK DK04714348T patent/DK1599167T3/da active
- 2004-02-25 RU RU2005129738/04A patent/RU2330023C2/ru not_active IP Right Cessation
- 2004-08-11 US US10/915,920 patent/US7501524B2/en not_active Expired - Fee Related
-
2005
- 2005-08-25 KR KR1020057015779A patent/KR101074579B1/ko not_active Expired - Fee Related
-
2008
- 2008-01-31 US US12/012,184 patent/US7501525B2/en not_active Expired - Fee Related
-
2009
- 2009-01-21 US US12/356,964 patent/US7816539B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0407726A (pt) | compostos, processo de preparação de um composto, composição farmacêutica e utilização de um composto | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| EA200400762A1 (ru) | Новые соединения, их использование в медицине, способ их изготовления и содержащие их фармацевтические композиции | |
| PH12012501351A1 (en) | Synthesis of eporthilones, intermediates thereto, analogues and uses thereof | |
| EA200301306A1 (ru) | Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение | |
| IL176247A0 (en) | Cyclopropane compounds and pharmaceutical use thereof | |
| PE20040644A1 (es) | Nuevos derivados de quinuclidina-amina | |
| EP3925614A3 (en) | Melanocortin receptor ligands | |
| TNSN07361A1 (en) | 3,4-substituted pyrrolidine derivatives for the treatment of hypertension | |
| ATE327229T1 (de) | Verbindungen und deren verwendung als 5-ht inhibitore | |
| MY143834A (en) | Thrombin receptor antagonists | |
| AU2003228770A8 (en) | Substituted pyrazolopyrimidines | |
| DE50310161D1 (de) | Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung | |
| ATE301117T1 (de) | Neue cyclopropane als cgrp-antagonisten, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung | |
| FR2850023B1 (fr) | Medicaments pour le systeme nerveux | |
| MXPA05013151A (es) | 3-fluoro-piperidinas como antagonistas de n-metil-d-aspartato/nr2b. | |
| ATE342264T1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
| TW200714598A (en) | Urea derivatives, methods for their manufacture, and uses therefor | |
| DE602004014727D1 (de) | Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon | |
| ATE444965T1 (de) | Sich als therapeutische mittel eignende arylalkylindole mit affinität für den serotoninrezeptor, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| FR2862971B1 (fr) | Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament | |
| ATE541839T1 (de) | Pyrrolidiniumderivate als m3-muskarinische rezeptoren | |
| ATE303991T1 (de) | Aralkyltetrahydropyridine, deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| DK1893620T3 (da) | Substituerede spiroforbindelser og disses anvendelse til fremstilling af smertestillende lægemidler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25D | Requested change of name of applicant approved |
Owner name: IPSEN PHARMA S.A.S. (FR) |
|
| B25G | Requested change of headquarter approved |
Owner name: IPSEN PHARMA S.A.S. (FR) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 12A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2364 DE 26-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |